|
Malignant neoplasm of prostate
|
0.340 |
Biomarker
|
disease |
BEFREE |
We noted statistically significant (P < 0.05) interactions between selenium assignment, SNPs in CAT, SOD2, PRDX6, SOD3, and TXNRD2, and high-grade prostate cancer risk.
|
27197287 |
2016 |
|
Malignant neoplasm of prostate
|
0.340 |
GeneticVariation
|
disease |
BEFREE |
Less common alleles of rs11913319 in TXNRD2 and rs125701 in OGG1 were associated with an increased risk of high-grade prostate cancer.
|
25284284 |
2015 |
|
Malignant neoplasm of prostate
|
0.340 |
Biomarker
|
disease |
BEFREE |
However, thioredoxin reductase 2 protein was clearly shown to be a biomarker of prostate cancer-associated reactive stroma whose presence distinguishes the stroma associated with benign prostatic hyperplasia from that associated with prostate cancer.
|
23762225 |
2013 |
|
Malignant neoplasm of prostate
|
0.340 |
GeneticVariation
|
disease |
BEFREE |
Among men carrying the variant allele for thioredoxin reductase 2 (TXNRD2) rs4485648, microsomal epoxide hydrolase 1 (EPHX1) rs17309872, or myeloperoxidase (MPO) rs11079344, an increased prostate cancer risk was observed with high, compared with no, petroleum oil/petroleum distillate (OR=1.9, 95% CI: 1.1-3.2, P interaction=0.01; OR=2.1, 95% CI: 1.1-4.0, P interaction=0.01), or terbufos (OR=3.0, 95% CI: 1.5-6.0, P interaction=2.0×10(-3)) use, respectively.
|
21716162 |
2011 |
|
Glaucoma, Primary Open Angle
|
0.330 |
GeneticVariation
|
disease |
BEFREE |
Apart from confirming evidence of association at TXNRD2 (rs16984299; OR<sub>[T]</sub> 1.20; P = 0.003), we found that a genetic risk score combining the effects of the 15 previously reported POAG loci was significantly associated with POAG in our samples (OR 1.56; 95% CI 1.26-1.93; P = 4.79 × 10<sup>-5</sup>).
|
30317457 |
2018 |
|
Glaucoma, Primary Open Angle
|
0.330 |
GeneticVariation
|
disease |
BEFREE |
Genome-wide association analysis identifies TXNRD2, ATXN2 and FOXC1 as susceptibility loci for primary open-angle glaucoma.
|
26752265 |
2016 |
|
Glaucoma, Primary Open Angle
|
0.330 |
GeneticVariation
|
disease |
BEFREE |
Recent GWAS completed for three types of common adult-onset glaucoma have identified novel loci for POAG (primary-open-angle glaucoma) (ABCA1, AFAP1, GMDS, PMM2, TGFBR3, FNDC3B, ARHGEF12, GAS7, FOXC1, ATXN2, TXNRD2); PACG (primary angle-closure glaucoma (EPDR1, CHAT, GLIS3, FERMT2, DPM2-FAM102); and exfoliation syndrome (XFS) glaucoma (CACNA1A).
|
28505344 |
2017 |
|
Familial glucocorticoid deficiency
|
0.320 |
GeneticVariation
|
disease |
BEFREE |
Mutations in TXNRD2 produced familial glucocorticoid deficiency (FGD) and dilated cardiomyopathy (DCM).
|
29709707 |
2018 |
|
Familial glucocorticoid deficiency
|
0.320 |
GeneticVariation
|
disease |
BEFREE |
Thioredoxin Reductase 2 (TXNRD2) mutation associated with familial glucocorticoid deficiency (FGD).
|
24601690 |
2014 |
|
Depressive Symptoms
|
0.310 |
Biomarker
|
phenotype |
BEFREE |
Six SNPs from the first of three COMT/TXNRD2 haploblocks interacted with depressive symptoms on TMD pain (smallest p-value: 2.7 × 10(-10) ).
|
22337325 |
2012 |
|
Cardiomyopathy, Dilated
|
0.120 |
GeneticVariation
|
group |
BEFREE |
Mutations in TXNRD2 produced familial glucocorticoid deficiency (FGD) and dilated cardiomyopathy (DCM).
|
29709707 |
2018 |
|
Cardiomyopathy, Dilated
|
0.120 |
GeneticVariation
|
group |
BEFREE |
Cardiac-specific deletion of Txnrd2 in mice results in dilated cardiomyopathy (DCM).
|
21247928 |
2011 |
|
Glaucoma
|
0.110 |
Biomarker
|
disease |
BEFREE |
Recent GWAS completed for three types of common adult-onset glaucoma have identified novel loci for POAG (primary-open-angle glaucoma) (ABCA1, AFAP1, GMDS, PMM2, TGFBR3, FNDC3B, ARHGEF12, GAS7, FOXC1, ATXN2, TXNRD2); PACG (primary angle-closure glaucoma (EPDR1, CHAT, GLIS3, FERMT2, DPM2-FAM102); and exfoliation syndrome (XFS) glaucoma (CACNA1A).
|
28505344 |
2017 |
|
Generalized Thyroid Hormone Resistance
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Resistance to thyroid hormone (RTH), a syndrome characterized by variable tissue hyposensitivity to thyroid hormone, is linked to mutations in the thyroid hormone receptor-beta (TR beta) gene.
|
7593433 |
1995 |
|
Generalized Thyroid Hormone Resistance
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Unlike the TR beta gene, a mutation in the TR alpha1 gene has never been found in patients with resistance to thyroid hormone (RTH).
|
9685218 |
1998 |
|
Generalized Thyroid Hormone Resistance
|
0.100 |
Biomarker
|
disease |
BEFREE |
In particular, the application of 3,3',5-triiodothyroacetic acid (Triac) in RTH due to defective TRβ and the role of 3,5-diiodothyropropionic acid (DITPA), 3,3',5,5'-tetraiodothyroacetic acid (Tetrac) and Triac in MCT8 deficiency will be highlighted.
|
28235578 |
2017 |
|
Generalized Thyroid Hormone Resistance
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To date, all individuals expressing the RTH phenotype have been found to harbor mutations in the thyroid hormone receptor beta (TR beta) gene that impair T3-mediated function.
|
8954015 |
1996 |
|
Generalized Thyroid Hormone Resistance
|
0.100 |
Biomarker
|
disease |
BEFREE |
The role of the TRβ was studied in cells from patients with resistance to thyroid hormone (RTH).
|
20827662 |
2011 |
|
Generalized Thyroid Hormone Resistance
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Mutations in the ligand-binding domain of the thyroid hormone receptor beta (TR beta) gene cause the syndrome of resistance to thyroid hormone (RTH).
|
8529109 |
1995 |
|
Generalized Thyroid Hormone Resistance
|
0.100 |
Biomarker
|
disease |
BEFREE |
Since similar mutations have been identified in tri-iodothyronine (T3) receptor (TR) beta gene in GRTH and PRTH, and since considerable overlap has been seen in the clinical manifestations in patients with GRTH and PRTH, two subtypes of RTH are now considered to be a continuous spectrum with the same genetic defect.
|
8958790 |
1996 |
|
Generalized Thyroid Hormone Resistance
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
TRβ gene mutation is not always correlated with the RTH phenotype.
|
25502991 |
2015 |
|
Generalized Thyroid Hormone Resistance
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Resistance to thyroid hormone (RTH) is a dominantly inherited syndrome characterized by hyposensitivity to thyroid hormone caused by mutations in the thyroid hormone receptor-beta (TR beta) gene.
|
8838149 |
1996 |
|
Generalized Thyroid Hormone Resistance
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Patients diagnosed as RTH with TRβ mutations were enrolled in a single institute between 2004 and 2014.
|
26041374 |
2015 |
|
Generalized Thyroid Hormone Resistance
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The aim of the study was to describe the clinical, biochemical, and genetic features of a sample of Mediterranean patients with RTH (resistance to thyroid hormone) due to mutations in TRβ (thyroid hormone receptor beta) referred to our institution during the last 15 years.
|
24722129 |
2014 |
|
Generalized Thyroid Hormone Resistance
|
0.100 |
Biomarker
|
disease |
BEFREE |
We have identified 20 different mutations in the thyroid hormone beta-receptor (TR beta) gene in RTH and assayed mutant receptor properties using the TSH alpha subunit gene promoter or promoters containing three different types of positive thyroid response element (TRE).
|
7838159 |
1994 |